Healthcare breaking news from MIP Diagnostics

MIP Diagnostics Ltd. this week announced the launch of its COVID-19 nanoMIP for diagnostic sensors, a synthetic alternative to antibodies that offers ultra-high sensitivity for the next wave of COVID-19 antigen detecting devices.

MIP Diagnostics has been able to fast-track the development of a high sensitivity antibody alternative thanks to the dedication of its scientists and backing of its investors, including Downing Ventures and BGF. This new solution will enable sensor developers to offer high performance devices for care homes, schools, and hospitals in the continual fight against coronavirus.

nanoMIPs are nanoscale Molecularly Imprinted Polymers, commonly known as synthetic antibodies. They are manufactured around a template molecule in a highly controlled chemical process. In this case, the nanoMIP has been manufactured around the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, specific to the COVID-19 virus.

The COVID-19 nanoMIP has now undergone significant testing and has demonstrated an ultra-low limit of detection of 5 fg/ml to the RBD spike protein in a sensor device.  Alongside this exceptional sensitivity performance, COVID-19 nanoMIPs also introduce an extra level of stability compared to biological receptors such as antibodies, and have been proven to withstand temperatures up to 121°C.

Alan Thomson, Chief Scientific Officer at MIP Diagnostics explained, ‘Molecularly imprinted polymers, such as the COVID-19 nanoMIP are extremely rigid and robust. This is hugely important for sensor devices as it means nanoMIPs can easily be coupled to the solid surface of the sensor electrode. This is much more challenging with natural receptors such as antibodies or nucleic acids since they easily denature during this coupling process, which inevitably impacts the success of the device.’

Stephane Argivier, Managing Director at MIP Diagnostics Ltd. said of the launch, “We are extremely excited to introduce a solution that will drive improvements to COVID-19 rapid test sensitivity. As the industry has learned, it is extremely important that accurate testing results during the full lifecycle of the infection are achieved, and high sensitivity COVID-19 sensors will enable this.’

He added, ‘The robust characteristics of nanoMIPs and chemical manufacturing processes also introduce a new level of supply consistency and security for device manufacturers that is difficult to achieve with biological receptors. This is especially important for COVID-19 antigen tests because of the huge demand and rapid manufacturing requirements we are currently seeing in the marketplace.”

Will Brooks, Investment Director at Downing Ventures commented “MIP Diagnostics demonstrate why they are the leaders of molecularly imprinted polymer technology with this fantastic development. We are proud to be working with them as they continue to make our world a safer one to live in with their innovative technology.”

The MIP Diagnostics Ltd. COVID-19 nanoMIP samples are now available for diagnostic sensor developers to test.

For more information, please visit https://www.mip-dx.com/


About MIP Diagnostics Ltd.

MIP Diagnostics is a technology leader in the field of Molecularly Imprinted Polymers (MIPs). The business has developed a novel, proprietary design and development process to make nanoMIPs; nano scale molecularly imprinted polymers that act as synthetic alternatives to antibodies. They are highly specific, sensitive, and robust, enabling new applications where antibodies have reached their limits. They are suitable for use in IVD assays, interference removal, biosensors and other industry applications. MIP Diagnostics offers a custom MIP development services and is now growing a portfolio of off-the shelf nanoMIPs to meet the needs of the IVD industry.

Date published:

20 Apr 2021

Practice area:

Healthcare